Cell-based regenerative medicine therapies require robust preclinical safety, efficacy, biodistribution 11 and engraftment data prior to clinical testing. To address these challenges, we have developed an 12 imaging toolbox comprising multi-spectral optoacoustic tomography and ultrasonography, which 13 allows the degree of kidney, liver and cardiac injury and the extent of functional recovery to be 14 assessed non-invasively in a mouse model of multi-organ dysfunction. This toolbox allowed us to 15 determine the therapeutic effects of adoptively transferred M2 macrophages. Using bioluminescence 16 imaging, we could then investigate the association between amelioration and biodistribution. 17 
Introduction 30
Cell-based regenerative medicine therapies (RMTs), which include pluripotent stem cells, 31 mesenchymal stromal cells and macrophages, have the potential to treat a variety of human diseases. 32
However, before these therapies can be routinely used in the clinic, accurate information regarding 33 their safety and efficacy should be obtained from appropriate preclinical models. It is also important 34 to gain an understanding of the therapeutic mechanisms of the RMTs, such as whether their ability to 35 ameliorate injury is dependent on their engraftment in the damaged tissues. Issues which currently 36 prevent the generation of such data include (i) the limitations associated with commonly used blood 37 biomarkers of organ injury, such as serum creatinine (SCr) for renal function ( (ii) the technical limitations in repeated blood and urine sampling in small rodents; and (iii) the 41 difficulties associated with monitoring organ function in small animal species longitudinally. The 42 assessment of organ injury in small rodents classically involves measurements of serum or urine 43 biomarkers, or histopathological analysis. Since the latter is usually only undertaken at post-mortem, 44 it fails to allow the progression of injury to be monitored in the same animals longitudinally, requiring 45 animals to be culled at multiple time points, which is not in keeping with NC3Rs' principles and also 46 reduces the power of the statistical tests. Furthermore, current methods make it difficult to assess the 47 safety, efficacy and therapeutic mechanisms of cell-based RMTs in comorbid conditions where more 48 than one organ is affected, such as in the cardiorenal and hepatorenal syndromes (Mayfield et al., 49 2016, Gonzalez-Calero et al., 2014, Erly et al., 2015) . 50
In this current study we set out to develop a multimodal imaging strategy to monitor the function of 51 the liver, kidney and heart longitudinally in BALB/c mice in a single imaging session. We utilised 52 multispectral optoacoustic tomography (MSOT) to assess kidney and liver function, and traditional 53 ultrasound (US) measurements to assess cardiac function. MSOT is a technique which uses multiple 54 excitation wavelengths to resolve specific sources of absorption, whether they are endogenous or 55 exogenous (Taruttis et al., 2012) . It relies on thermoelastic expansion which occurs when energy from 56 a laser capable of emitting light at a range of wavelengths is absorbed by molecules within the tissues. 57
This causes electrons to move to an excited state, generating heat and a resultant pressure wave 58 which is detected by an ultrasound detector. The specific absorption profile of endogenous or 59 5C) whereas ADR and ADR+BMDM mice showed evidence of hepatocellular degeneration (Fig 5(1) ) 155 and necrosis (Fig 5D(2) ). Histological scoring in both the kidney and liver showed that control mice had 156 no evidence of histological damage whereas both the ADR and ADR+BMDM groups showed varying 157 degrees of injury (Fig 5E, F respectively) . 158
Bioluminescence imaging shows that BMDMs accumulated in the kidneys and liver following ADR-159 induced injury, but not in the heart 160 In order to investigate the effect of organ injury on BMDM distribution, mice were imaged on the 161 same day, or 3 days after administration of luciferase+ BMDMs, which corresponded to the 1 st and 4 th 162 day following saline or ADR administration. Bioluminescence imaging showed that on day 1, cells were 163 mostly in the lungs of both control and ADR animals. By day 4, BMDMs were no longer detectable in 164 the controls, but had a widespread distribution in the ADR group (Fig 6A, B) . Given the poor spatial 165 resolution of bioluminescence imaging, it was not possible to determine which organs the BMDMs 166 had populated in the ADR group at day 4. Therefore, immediately after in vivo imaging on day 1, three 167 animals were immediately sacrificed to quantify the biodistribution of BMDMs in the major organs ex 168 vivo, with the remaining three mice being sacrificed on day 4. Similarly to the in vivo data, ex vivo 169 analysis of organs on day 1 showed no obvious difference between control and ADR mice, with most 170
BMDMs being in the lungs, and some detected in the spleen (Fig. 6C, D) . By day 4, BMDMs could only 171 be detected in the lungs of control animals, but were present in the lungs, spleen, kidneys and liver of 172 ADR animals. BMDMs were not detected in the hearts of control or ADR animals (Fig. 6E, F) . 173
We measured the total flux from the individual organs ex vivo to quantify the differences in organ 174 biodistribution between the treatment groups and time points (Fig. 7) . The total flux from the heart, 175 lungs and spleen decreased between days 1 and 4 in both the control and ADR mice (Fig 7A, B, C) . The 176 same trend was observed for the liver and kidney in the controls, with total flux decreasing between 177 days 1 and 4. On the other hand, in the ADR mice, total flux increased significantly in the liver and 178 kidneys between days 1 and 4 (Fig 7D, E) . function when compared to control mice. The AUC C:P showed a strong positive correlation with a 209 more traditional biomarker of kidney injury, BUN, which reinforces the utility of AUC C:P as a measure 210 of kidney function. There were, however, no differences between the mean BUN measurements in 211 mice which received adriamycin alone and those which received adriamycin and M2 BMDMs. SCr was 212 not significantly different between any of the groups, which highlights the lack of sensitivity of this 213 biomarker for indicating renal function in rodents. Histological analyses of the kidneys showed 214 evidence of intratubular protein casts and flattening of tubular epithelium in mice which received 215 adriamycin, irrespective of whether they were administered BMDMs or not. Therefore, although 216 MSOT showed that the M2 BMDMs appeared to cause a subtle improvement in renal function, there 217 was no corresponding improvement in histological damage or BUN levels. A study by Lu and colleagues 218 had previously demonstrated that M2 macrophages reduce inflammatory infiltrates in adriamycin-219 induced nephropathy; however, macrophages were not administered until 5 days after adriamycin 220 administration and biomarker analyses not carried out until day 28 (Lu et al., 2013) . It is possible in 221 this current study that analysis of kidney function at later time points than day 4 may have yielded 222 more significant improvements in function. Wang and colleagues studied the effect of M0, M1 and 223 M2 activated macrophages in a mouse model of chronic adriamycin nephropathy (Wang et al., 2007) . 224
These authors had found that by 4 weeks, M0 macrophages had no effect on renal injury, while M1 225 macrophages promoted histological damage, and M2 macrophages significantly ameliorated tubular 226 and glomerular injury (Wang et al., 2007) . By contrast, we failed to observe any ameliorative effects 227 of the M2 macrophages on tissue damage, but this may have been because our analysis was 228 performed at 4 days, rather than at 4 weeks. Consistent with our current study, Wang and colleagues 229
showed that M2 macrophages trafficked to inflamed kidneys. In addition, they provided evidence that 230 the exogenous M2 macrophages ameliorate injury by reducing the infiltration of resident 231 macrophages, thereby reducing inflammation. 232
In the current study the clearance of ICG from the blood of mice was used as a measure of liver IV administration. However, in mice which received adriamycin this was not the case; luminescence 269 was detected over the whole body of the mouse when imaged in vivo, and in the liver, kidneys, lungs 270 and spleen, but not the heart, when imaged ex vivo. While the luminescent signal intensity decreased 271 from day 1 to 4 in the lungs and spleen, it was still observable. On the other hand, the signal intensity 272 in the liver and kidneys was significantly elevated between days 1 and 4. Of note, the total flux in the 273 whole body images on day 4 in ADR treated mice appeared greater than on day 1; however M2 274 BMDMs do not have a great proliferative capacity so this was likely a result of the weight loss in the 275 ADR treated mice causing less attenuation of light. 276
Summary 277
This investigation demonstrates that changes in the function of the liver, kidney and heart can be 278 tracked over time in individual healthy animals and those that have received a single high dose of 279 adriamycin. We show that these changes in liver and kidney function correlate well with traditional 280 serum biomarkers of injury and show histological evidence of injury. We also show that the addition 281 of M2 BMDMs improves kidney and liver function over the study as measured by MSOT. However 282 neither biomarker nor histological analyses showed a reduction in the severity of injury. This may 283 suggest that subtle changes in organ function can be detected using MSOT imaging prior to changes 284 in organ histopathology and accumulation of serum biomarkers. Therefore, MSOT allows the 285 assessment of the efficacy of a potential RMT in mice without the need for repeated blood or urine 286 sampling. Secondly this study demonstrates an imaging technique to monitor the biodistribution of 287 M2 BMDMs in healthy animals and those with organ dysfunction. Unfortunately, to accurately assess 288 the intra-organ biodistribution of M2 BMDMs, it is required that animals are sacrificed prior to 289 imaging. We show that adriamycin affected the biodistribution of M2 BMDMs since mice with kidney 290 and liver dysfunction demonstrated an increase in longevity and migration of the therapeutic cells to 291 both organs, which incidentally also appeared to provided signs of efficacy in the functional study. No 292 signs of efficacy were observed in the heart, which showed no evidence that BMDMs migrated 293 towards it. 294
This current study describes and demonstrates an "imaging toolbox" to assess murine renal, hepatic 295 and cardiac function in a minimally invasive manner using both MSOT and ultrasound in a single 296 anaesthesia session. Comorbidities are common clinically so the ability to utilise an imaging toolbox 297 to investigate the potential of regenerative therapies in preclinical species is crucial. This toolbox 298 allows more accurate assessment of the efficacy of potential regenerative therapies than current 299 histological and biomarker analyses as it allows the extent of the recovery to be measured in individual 300 animals over time. Many regenerative therapies which show efficacy in preclinical species are not 301 effective clinically which may be a result of improper methods to assess their efficacy in individual 302 animals preclinically. This toolbox may allow more accurate assessment of efficacy and enable a more 303 robust determination of the risk: benefit ratio of a potential regenerative therapy prior to clinical 304 translation and therefore reduce the number of therapies that don't show true efficacy that are tested 305 in human patients. This toolbox also improves understanding of the mechanism in which cell therapies 306 elicit efficacy through the study of their biodistribution. We can determine whether cells must reach 307 the target organ and engraft to show efficacy, which is important for determining the optimal 308 administration route. 
Materials and Methods 316 Animals 317
Mice were purchased from Charles River, UK, and were housed with ad libitum access to food and 318 water. All animal experiments were performed under a license granted under the Animals (Scientific 319 Procedures) Act 1986 and were approved by the University of Liverpool ethics committee. 320
Experiments are reported in line with the ARRRIVE guidelines. 321
Primary macrophage isolation 322
Primary bone marrow derived macrophages (BMDMs) were prepared as previously described 323 (Sharkey et al., 2017) . Male BALB/c mice were used to isolate BMDMs for the efficacy study whereas 324 for the biodistribution study, mice with a mixed background (L2G85 mice bred to wild type FVB mice) 325 expressing the CAG-luc-eGFP L2G85 transgene were used (FVB-Tg(CAG-luc,-GFP)L2G85Chco/J). 326
Briefly, femurs and tibias of mice (8-10 weeks) were harvested and muscle tissue removed from the 327 bones in a sterile fume hood. Bone marrow was flushed from the bones using a sterile syringe with 328 Dulbecco's Modified Eagle's Medium (DMEM): F12 cell culture medium (Gibco) supplemented with 329 10 % foetal bovine serum 2mM glutamine and 1 x penicillin/streptomycin (Invitrogen). The bone 330 marrow was suspended in the medium before being passed through a cell strainer (40 μm) and then 331 cultured in DMEM: F12 media containing 20 ng/ml murine recombinant macrophage colony 332 stimulating factor (MCSF-1). Bone marrow suspensions were cultured at 37 °C, 5 % CO2 and medium 333 was replaced every other day. On day 7, macrophages were considered fully differentiated as 334 determined by the expression of both CD11b and F4/80 (Biolegend) by flow cytometry. Mature 335 BMDMs were then polarised towards an M2-like phenotype by the overnight addition of recombinant 336 murine interleukin (IL)-4 (20 ng/ml). 337
Induction of organ dysfunction 338
Male BALB/c mice (8 -10 weeks) received either adriamycin (20 mg/kg, n=11) or saline (0.9 %, n=4) 339 intra-peritoneally (IP) on day 0. Adriamycin (doxorubicin hydrochloride, Tocris Bioscience) was 340 dissolved in warm saline (0.9 %) to make a stock solution (10 mg/ml) before administration. Mice were 341 weighed on a daily basis to monitor their wellbeing and mice which received adriamycin were provided 342 with a wet food diet. 343
Imaging protocol 344
Imaging was carried out on day 1 and 4 under the same imaging session and using the following 345 protocol: Mice were anaesthetised and fur was removed from the torso by shaving and epilating. Mice Cardiac function was assessed using the Prospect 2.0 ultrasound system (S-Sharp, Taiwan). Mice were 356 anaesthetised using isofluorane and oxygen and the mice were placed dorsally on a heated platform. 357
Mice were fixed in place during imaging using surgical tape. Ultrasound gel was applied to the chest 358 area of the mice and the ultrasound transducer positioned above the chest area. The following 359 parameters were measured: epicardial area and endocardial area in the long axis view, left ventricle 360 length, epicardial areas in the short axis view, M-mode images of both the long and short axis views 361 in order to measure heart rate, left ventricular interior diameter and wall thickness in both diastole 362 and systole. These parameters were used to calculate fractional shortening (FS), ejection fraction (EF), 363 stroke volume (SV) and cardiac output (CO). 364
Assessment of liver function 365
Liver function was assessed using the inVision 256-TF MSOT imaging system (iThera Medical, Munich). 366
Immediately after assessment of cardiac function the mice were moved to the MSOT imaging system. 367
Prior to being placed into the system the tail vein of the mice was cannulated to allow injection of the 368 optical imaging contrast agents during photoacoustic imaging. Mice were placed in the system and 369 allowed to acclimatise for 15 minutes prior to recording data. Imaging focussed on the ischiatic vessels 370 close to the hips of the mice for detection of indocyanine green (ICG) and its subsequent clearance. 371
The following parameters were used: an acquisition rate of 10 frames per second (consecutive frames 372 averaged to minimalise effects of respiration movement), with wavelengths of 700, 730, 760, 800, 850 373 and 900 nm being recorded. Data were recorded for 3 minutes prior to intravenous (IV) injection of 374 ICG (40 nmol, 100 μl) over a 10 s period. Data were reconstructed using a model linear algorithm (View 375 MSOT software) and multispectral processing using linear regression for ICG, deoxy-and oxy-376 haemoglobin spectra to resolve the signal for the ICG dye. Regions of interest drawn around the 377 ischiatic vessels of each mouse were used to quantify the ICG dye signal (as mean pixel intensity) inthe vessels of the mice. These data were used to calculate the area under the clearance curve (AUC). from typical sections of a kidney from a healthy mouse (A), the kidney of a mouse which had received 590 adriamycin (B), the liver of a healthy mouse (C) and the liver of a mouse which had received adriamycin 591 (D1, 2). All organs were collected on day 4 of the study and were stained with haematoxylin and eosin. shown (E, F respectively). Each data point represents an individual animal. 597
